
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics demonstrated a significant operational improvement in 2Q25, with the sale of 7,233 nanochannel array flowcells reflecting a 17% increase from the previous year. Adjusted revenue from consumables, software, and other services grew by 11% year-over-year, driven by a robust 16% increase in consumables and software revenues. Additionally, the company expects new OGM installations to rise to between 20 and 25 in FY2025, up from an anticipated range of 15 to 20, indicating positive momentum in its product offerings and market demand.
Bears say
Bionano Genomics Inc. faces significant risks that contribute to a negative outlook on its stock, including potential lower-than-expected market uptake of its products and reduced utilization of installed systems. The company's projections indicate a price objective of approximately $11, based on conservative revenue multiples and current financial metrics, which raises concerns about its capacity to achieve these targets amid operational challenges. Additionally, the need to secure further capital poses a threat to financial stability, coupled with the risk of shareholder dilution, all of which could hinder the company's growth and investor confidence.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares